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Sansanmycin natural product analogues as potent
and selective anti-mycobacterials that inhibit
lipid I biosynthesis
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Tuberculosis (TB) is responsible for enormous global morbidity and mortality, and current
treatment regimens rely on the use of drugs that have been in use for more than 40 years.
Owing to widespread resistance to these therapies, new drugs are desperately needed to
control the TB disease burden. Herein, we describe the rapid synthesis of analogues of the
sansanmycin uridylpeptide natural products that represent promising new TB drug leads. The
compounds exhibit potent and selective inhibition of Mycobacterium tuberculosis, the
etiological agent of TB, both in vitro and intracellularly. The natural product analogues are
nanomolar inhibitors of Mtb phospho-MurNAc-pentapeptide translocase, the enzyme
responsible for the synthesis of lipid I in mycobacteria. This work lays the foundation for the
development of uridylpeptide natural product analogues as new TB drug candidates that
operate through the inhibition of peptidoglycan biosynthesis.
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T
uberculosis (TB) is caused by infection with the bacterium
Mycobacterium tuberculosis (Mtb) and, according to
the World Health Organization, was responsible for 1.5
million deaths and the emergence of 9.6 million new cases of the
disease in 2014 (ref. 1). Current treatment for TB relies on a
6-month quadruple therapy comprising rifampicin, isoniazid,
ethambutol and pyrazinamide2. Despite achieving a cure rate of
495% for drug-sensitive TB, this regimen is not effective against
multi-drug resistant (MDR) and extensively drug resistant (XDR)
TB infections, which are emerging at an alarming rate globally.
While MDR infections can be treated with second-line antibiotics
for extended periods, XDR infections are virtually untreatable as
exempliﬁed by a 98% mortality rate in a recent outbreak in South
Africa3. To effectively combat these drug resistant cases, new TB
drugs with novel modes of action are desperately needed. Two
compounds, bedaquiline and delamanid, were recently approved
for drug resistant TB; however these are only used as drugs of last
resort owing to reported toxicity issues4.
It is well established that natural products provide a rich
resource for the discovery of new drug leads5,6. Approximately
65% of antibacterials approved for use between 1981 and 2010
were natural products or natural product derivatives5,6, including
currently employed TB drugs for example, rifampicin and the
aminoglycosides. The sansanmycins belong to the uridylpeptide
natural product family, a sub-class of the structurally diverse
nucleoside antibiotics7,8 that include the liposidomycins9, capra-
zamycins10, capuramycins11,12 and muraymycins13. The sansa-
nmycins are produced by the soil bacterium Streptomyces sp.14–16
and have a number of interesting structural features that are
unique to the uridylpeptide natural product family. These include
a 30-deoxyuridine motif appended to N-methyl-2,3-diamino-
butyric acid (DABA) via an unusual cis-40,50-enamide linkage.
The DABA moiety is found within a ‘pseudo-tetrapeptide’ chain
which possesses the sites of variation in the family7. In addition to
these fascinating structural features, the natural products have
been shown to possess signiﬁcant activity against Mtb, including
MDR strains14,15. For these reasons we became interested in the
sansanmycin scaffold as a privileged starting point for the
discovery of novel TB drug leads.
In this manuscript we describe the rapid synthesis of a library
of sansanmycin analogues that exhibit potent and selective
activity against the virulent H37Rv strain of Mtb. We show
that these natural product analogues disrupt the activity of Mtb
phospho-MurNAc-pentapeptide translocase (variously desig-
nated as MurX in mycobacteria, MraY or translocase I in the
literature), the integral membrane enzyme responsible for the
biosynthesis of lipid I, a key intermediate in mycobacterial
peptidoglycan synthesis.
Results
Anti-mycobacterial activity of dihydrosansanmycin A–C. Our
initial goal focused on gaining access to structural analogues
of the sansanmycin uridylpeptide natural product family (for
example, analogues of sansanmycin A–C 1–3 (refs 14,15), Fig. 1).
To date, several derivatives of uridylpeptide natural products have
been generated through engineering of the organisms that
produce the natural products or through semi-synthetic approa-
ches and, as such, feature limited structural variation17–25.
A number of synthetic studies have also been reported on
uridylpeptide natural products and analogues26–33, some of
which have been shown to possess antimicrobial activity7,8. The
focus of the present study was to develop a rapid and divergent
synthetic strategy to access a diverse library of sansanmycin
analogues that would enable the determination of key structure-
activity relationships speciﬁcally against Mtb. In previous studies
it has been shown that dihydropacidamycin analogues, lacking
the enamide linkage maintained activity against Pseudomonas
aeruginosa23. Given the potential metabolic lability of the
enamide, we chose to target dihydrosansanmycin analogues
in this study. Following the preparation of the ﬁrst targets
(Supplementary Methods) dihydrosansanmycins A–C (4–6),
screening against the virulent H37Rv strain of Mtb was
conducted using a resazurin assay34 (Fig. 1). These compounds
were also counter-screened against HEK293 cells to gauge
selectivity (Supplementary Methods). We were pleased to ﬁnd
that sansanmycin analogues 4–6 exhibited signiﬁcant inhibitory
activity against Mtb, with dihydrosansanmycin A (4) and B (5)
possessing nanomolar MIC50 values (Fig. 1). Crucially, the
stereochemistry at C-40 of the ribose moiety was shown to be
essential for anti-mycobacterial activity, with S-conﬁguration in a
dihydrosansanmycin B analogue leading to complete loss of
activity (Supplementary Fig. 30). Interestingly, the importance of
stereochemistry at C-40 has also been reported for dihydro-
pacidamycin, whereby analogues with S-stereochemistry at this
position exhibited reduced activity against P. aeruginosa
compared with the corresponding R-epimer23.
Synthesis and activity of dihydrosansanmycin analogues.
Encouraged by the promising anti-mycobacterial activity of
dihydrosansanmycin B (5), we next focused on the preparation of
a targeted library of analogues of 5 to delineate the functional
importance of the non-proteinogenic amino acid m-tyrosine
(m-Tyr). As such, analogues 7–17, retaining the DABA unit
(due to the previously established importance of the N- and
b-methyl moieties for activity28,32,33) but possessing a variety of
functionalities in place of the m-Tyr moiety, were proposed
(Fig. 2). Here, we took the opportunity to develop a robust
divergent route to rapidly access the analogues. Preparation of
7–17 began with the synthesis of fully protected isopeptide
fragments via Fmoc-strategy solid-phase peptide synthesis on
2-Cl Trt Cl resin. This was followed by late stage coupling of
40-deoxyuridine fragment 18 which was synthesized from uridine
in 12 steps using modiﬁcations to a method reported by
Boojamra et al.23 (Fig. 2, Supplementary Methods). Two
approaches were employed to access members of the library.
The ﬁrst involved coupling of suitably protected preformed
isopeptide building blocks with a variety of amino acids appended
to the DABA unit (general structure 19). The second strategy
involved the installation of allyloxycarbonyl (Alloc)-protected
DABA fragment 20 onto the solid phase. This enabled late stage
divergent access to the desired pseudopeptidic structures through
en bloc Pd(0) deprotection followed by coupling of a variety of
amino acids (R1 in Fig. 2, Supplementary Methods).
Following synthesis and puriﬁcation by reverse-phase HPLC,
analogues 7–17 were assessed against Mtb (H37Rv). We were
pleased to ﬁnd that most of the analogues retained signiﬁcant
activity against Mtb, albeit with a relatively ﬂat structure-activity
proﬁle, with MIC50 values ranging from 0.6 to 9.80 mM for the
series (Fig. 2). The incorporation of alternative aromatic
substituents in compounds 7–9 proved to be detrimental with
over an order of magnitude drop in activity. Incorporation of
cyclohexyl-Ala (10), cyclohexyl Gly (11), Lys (15), Orn (16) or
Thr (17) residues in place of m-Tyr did not lead to an appreciable
decrease in activity (MIC50¼ 0.95–1.35 mM), with the exception
of the negatively charged Asp residue in 14 which led to a
signiﬁcant drop in potency. Interestingly, the replacement of
m-Tyr with amino acids with smaller side chains for example,
Gly in 12 (MIC50¼ 0.63 mM) and Ala in 13 (MIC50¼ 0.60 mM),
provided anti-mycobacterials that were more potent than other
substitutions at this position. As with dihydrosansanmycin A–C
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(4–6), compounds 7–17 were not cytotoxic to HEK293 cells up to
a concentration of 200 mM. Given the promising activity of the
natural product analogues against Mtb, we were next interested
to assess the antimicrobial activity against other pathogenic
bacteria to gauge whether there was any selectivity in activity.
Towards this end, we counter-screened 4–17 against a panel of 15
pathogenic Gram-negative and Gram-positive bacterial strains
using a high throughput screen, including several ‘ESKAPE’
pathogens of clinical relevance35. The organisms in the screen
included: Bacillus subtilis, Staphylococcus aureus, methicillin-
resistant S. aureus (MRSA), Staphylococcus epidermidis, Listeria
ivanovii, Enterococcus faecium, Escherichia coli, Vibrio cholerae,
Salmonella typhimurium, Pseudomonas aeruginosa, Yersinia
pseudotuberculosis, Providencia alcalifaciens, Ochrobactrum anth-
ropi, Enterobacter aerogenes, Acinetobacter baumannii. Remar-
kably, while a small number of compounds exhibited modest
activity against E. coli and P. aeruginosa (MIC50s: 12.5–100 mM),
most did not inhibit the growth of other strains up to
concentrations of 100 mM (Supplementary Tables 1 and 2). This
selective anti-mycobacterial activity is an important criterion for
the development of a TB drug lead and, as such, was a particularly
encouraging observation.
Second-generation dihydrosansanmycin analogues. Because
substitution of the synthetically challenging m-Tyr residue in 5
with a Gly residue in 12 did not lead to a substantial drop in anti-
mycobacterial activity, we chose to maintain Gly at this position,
and modify the Leu residue within the peptide chain (R in Fig. 1),
in a second generation compound library. Speciﬁcally, a number
of alkyl, heteroalkyl, aryl and heteroaryl substituents were pro-
posed in analogues 21–36 with a view to interrogating further
SARs. Dihydrosansanmycin analogues 21–36 were synthesized
using the divergent solid-phase strategy described above
(Supplementary Methods) and assessed for anti-mycobacterial
activity against Mtb H37Rv (Fig. 3). Substitution of the isopropyl
sidechain in 12 with different alkyl side chains in 21–24 did
not lead to substantial differences in activity with MIC50 values
ranging from 510 to 930 nM. Interestingly, extension of the
cyclohexyl Gly side chain in 24 with a cyclohexyl Ala moiety led
to a substantial increase in potency with analogue 25 exhibiting
an MIC50 of 80 nM against Mtb. The introduction of more polar
substituents, for example, a Thr side chain in 26 or an Asp
residue in 27 led to a signiﬁcant drop in activity (MIC50¼ 2.80
mM and 46.25 mM, respectively) when compared with original
lead 12. A similar drop in activity was not observed when a Lys
residue was introduced in 28 which was equipotent to 12
(MIC50¼ 700 nM). Incorporation of aryl and heteroaryl groups
in 29–36 in place of the Leu residue in 12 generally gave rise to
improved anti-mycobacterial activity. Indeed, introduction of a
Phe residue in 29 or a p-CF3 Phe residue in 30 led to a two-fold
improvement in activity compared with 12. Substitution with
Tyr (31), 3-pyridyl Ala (32) and Trp (33) residues led to a modest
drop in activity against Mtb compared with 29 (MIC50¼
0.44–0.98 mM). Shortening the side chain of Phe derivative 29
with a phenyl Gly side chain in 34 resulted in a dramatic drop in
activity (MIC5046.25 mM). This is in line with the reduced
activity observed when shortening the side chain in the homo-
logous analogues 24 and 25 with saturated cyclohexyl function-
alities. Extending the Phe side chain in 29 by a further methylene
unit in homo-Phe derivative 35 led to a four-fold loss in activity,
while the incorporation of a naphthyl Ala side chain in 36 pro-
vided the most potent compound in the aryl substituted series
with an MIC50 of 180 nM against Mtb. As with the ﬁrst genera-
tion series of dihydrosansanmycin analogues, 21–36 did not show
any activity (up to 200mM) against HEK293 cells, and exhibited
poor or no activity against the 15 pathogenic Gram-positive and
Gram-negative bacterial strains (Supplementary Tables 1 and 2).
On the basis of the ﬁrst generation (7–17, Fig. 2) analogue
library, the optimal isopeptide substitution on the DABA unit was
m-Tyr (found natively in the sansanmycins), whilst in the second
generation library (21–36, Fig. 3), a cyclohexyl Ala residue
provided the most potent anti-mycobacterial activity. With this in
mind, analogue 37 was designed and synthesized that incor-
porated both of these functionalities (Fig. 3, Supplementary
Methods). Gratifyingly, this analogue possessed the most potent
activity against Mtb of all the natural product analogues
synthesized with an MIC50 of 37 nM.
Mechanism of action of sansanmycin analogues. It has been
hypothesized that the antibacterial mechanism of action of
the nucleoside antibiotic family is via inhibition of translocase
I (MraY), an integral membrane protein that transfers UDP-
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Figure 1 | Structures of sansanmycins A-C (1–3), synthetic dihydrosansanmycins A–C (4–6) and inhibitory activity against Mtb H37Rv. MIC values of
isolated sansanmycins A–C (1–3) were previously reported by Xie et al.14,15 MIC50 values of 4–6 represent the average of two independent experiments,
each performed in triplicate; positive controls RIF: MIC50¼0.006±0.002mM; INH: MIC50¼0.025±0.005mM; MIC50 (HEK293) for 4–64200mM.
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MurNAc pentapeptide to polyisoprenylphosphate phosphate to
afford lipid I, thereby catalysing the ﬁrst membrane-associated
step of peptidoglycan biosynthesis (Fig. 4a)7. Whilst inhibition of
MraY has been unequivocally determined for some members of
the family8,25,28,36–38, including a recently published structure of
a complex of muraymycin D2 with the Aquifex aeolicus
enzyme25, the antibacterial activity of other nucleoside anti-
biotics, including the sansanmycins, have only been predicted to
be caused by inhibition of this enzyme. Furthermore, structural
analogues of the nucleoside antibiotics have, on several occasions,
been shown not to inhibit MraY, but to target other essential
enzymes, suggesting that structural changes to the natural
product can attenuate and even switch activity to other
bacterial enzymes39,40. We were therefore interested in
assessing the inhibitory activity of dihydrosansanmycin
analogues 7–17 and 21–37 against Mtb translocase I. It is
important to note that while the translocase I enzyme is dubbed
MraY in most organisms, in mycobacteria this enzyme is encoded
by the murX gene and is therefore referred to as MurX. An assay
was developed to assess the inhibitory activity of the natural
product analogues against Mtb MurX in an initial screen.
Consistent with prior work on MraY orthologues of Mtb MurX
(ref. 41), we were unable to overexpress the enzyme and therefore
opted to assay the native enzyme in mycobacterial membranes.
Brieﬂy, Mtb mc2 6230 membrane protein preparations were
generated that contained MurX, along with other membrane
proteins (including MurG, the enzyme that generates lipid II
from lipid I, Fig. 4a). The inhibition of MurX was assessed in a
MurX–MurG coupled assay whereby a decrease in lipid II
formation was monitored by radiochemical means. Because the
nucleoside antibiotics have only been demonstrated to inhibit
MurX, we made the assumption that, despite the coupled nature
of the assay, it would serve to effectively measure the inhibition of
MurX. The assay was initially performed by the addition of a
200 nM concentration of a given sansanmycin analogue together
with UDP-[14C]GlcNAc and UDP-MurNAc pentapeptide (Park’s
nucleotide). Following quenching of the enzymatic reactions and
an extraction-based work up, thin layer chromatography (TLC)
and phosphorimaging were used to measure the degree of
inhibition of MurX by measuring a decrease in the formation of
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lipid II that incorporated the [14C] label on the GlcNAc moiety
(Fig. 4b). We were pleased to observe that all the natural products
inhibited MurX to varying degrees in this assay (9–100% MurX
inhibition at 200 nM, Supplementary Tables 3–5). Importantly,
the most potent analogues against Mtb growth were also the most
active MurX inhibitors in this screen (Supplementary Figs 38
and 39). In a recent report by Ishizaki et al., CPZEN-45, an
analogue of the caprazamycin family of nucleoside antibiotics was
shown not to inhibit MurX in M. smegmatis, but rather inhibited
WecA, an enzyme involved in arabinogalactan biosynthesis in
mycobacteria40. WecA also uses UDP-GlcNAc as a substrate but,
unlike MurX, does not utilize Park’s nucleotide. As such, we also
assessed inhibition of WecA by the sansanmycin analogues in our
assay40. Interestingly, we did not observe inhibition of WecA by
any of the compounds and, as such, the natural product
analogues appear to be selective inhibitors of lipid I formation
in peptidoglycan biosynthesis.
Having established inhibition of Mtb MurX by the dihydro-
sansanmycins at a single concentration, we next focused on three
analogues which showed the most potent inhibition of Mtb and
Mtb MurX in vitro (compounds 25, 36 and 37). The TLC-based
assay developed above was employed using a range of concen-
trations of a given analogue and IC50 values of 54, 48 and 41 nM
were determined for 25, 36 and 37, respectively (see Fig. 4b for
assay plate for compound 37). Importantly, there was signiﬁcant
correlation between the IC50 against Mtb MurX and the activity
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against Mtb H37Rv in vitro. To unequivocally determine that our
lead sansanmycin analogues were inhibiting Mtb MurX exclu-
sively (and not a combination of MurX and MurG), we
established a complementary ﬂuorescence-enhancement assay
which measured the incorporation of an N-dansylated UDP-
MurNAc pentapeptide (dansylated on the diaminopimelic acid
moiety) using a modiﬁcation to an assay reported for the E. coli
orthologue by Bugg and co-workers42. Brieﬂy, Mtb mc2 6230
membranes were incubated with one of the lead analogues
(compounds 25, 36 or 37) and the N-dansylated UDP-MurNAc
pentapeptide substrate and formation of lipid I monitored by
excitation at 340 nm and detection at 530 nm. Gratifyingly, the
ﬂuorescence assay of 25 (IC50¼ 30 nM), 36 (IC50¼ 14 nM) or 37
(IC50¼ 16 nM) demonstrated similar inhibitory potencies to
those determined via the radiochemical assay. Importantly,
these data verify that the compounds are selective inhibitors of
Mtb MurX and that this is likely the mechanism of anti-
mycobacterial activity. Furthermore, the development of this
ﬂuorescence assay now provides a higher throughput means to
screen future Mtb MurX inhibitors.
Intracellular anti-mycobacterial activity of lead analogues.
Having established that the three lead analogues were potent
inhibitors of Mtb MurX, they were next assessed for their
anti-mycobacterial activity in an intracellular assay. Speciﬁcally,
THP-1 macrophages were infected withMtb and the inhibition of
mycobacterial growth measured in the presence of a range of
concentrations of 25, 36 or 37. Gratifyingly, all of the natural
product analogues maintained anti-mycobacterial activity intra-
cellularly with IC50s of 1.57, 4.33 and 0.11 mM for 25, 36 and 37,
respectively (Supplementary Figs 31–33). This data provides
encouragement that these compounds may serve as bonaﬁde
leads for future TB drug discovery efforts.
Stability studies. We ﬁnally assessed the stability of 25, 36 and 37
in mouse and human plasma and mouse and human liver
microsomes with each of the compounds showing excellent sta-
bility, with degradation half-lives of 47 h for human and mouse
plasma and 4160min for human and mouse liver microsomes
(Supplementary Tables 6 and 7). Based on the potent inhibition
of Mtb (both in vitro and intracellularly) and the promising
stability data, these compounds now serve as exciting leads for the
development of a further generation of sansanmycin derivatives
with a view to developing a TB drug lead which operates through
the inhibition of lipid I synthesis in Mtb.
Discussion
In summary, we have described the development of a robust
divergent solid-phase synthetic strategy to rapidly access a library
of dihydrosansanmycin natural product analogues. A number of
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analogue 37 (IC50¼41 nM). Positive control¼ pacidamycin D19 and tunicamycin. Ala, alanine; Glu, glutamate; mA2P, meso-diaminopimelic acid. Product
of MurX¼decaprenyldiphosphoryl-MurNAc-pentapeptide (lipid I), product of MurG¼ decaprenyldiphosphoryl-MurNAc-pentapeptide-GlcNAc (lipid II),
product of WecA¼ decaprenyldiphosphoryl-GlcNAc. (c) Inhibition assay of Mtb MurX with dihydrosansanmycin analogue 37 (IC50¼ 16 nM)
using dansylated UDP-MurNAc pentapeptide as substrate. Km(app) UDP-MurNAc-pentapeptide¼ 51±4mM and Vmax(app)¼ 69±1.9mMmin 1;
Km(app) polyisoprenylphosphate¼ 56±9mgml 1 (Supplementary Figs 40 and 41). Positive control tunicamycin: IC50¼ 189 nM (Supplementary Fig. 46).
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potent inhibitors ofMtb were elucidated that possess activity both
in vitro and in macrophages infected with the organism. The
compounds were shown to potently inhibit the enzyme MurX,
responsible for lipid I synthesis, a key intermediate en route to
peptidoglycan in Mtb. Despite this mechanism of action, the
natural product analogues possess selective activity against Mtb,
with little to no activity against other pathogenic bacteria that also
synthesize peptidoglycan. This selectivity provides a practical
advantage for the potential use of these compounds as TB drugs
as well as MurX as a TB drug target. Future work in our
laboratories will focus on understanding the mechanism of this
selectivity. Finally, the compounds were stable in plasma and
against the action of liver microsomes which, together with the
potent and selective activity against Mtb, lays the foundation for
the development of TB drug leads based around this natural
product scaffold in the future.
Methods
Synthesis of sansanmycin analogues. For materials, methods and complete
details of synthetic procedures, see Supplementary Methods. 1H, 13C and 2D NMR
spectra of compounds described in this manuscript can be found as Supplementary
Figs 47–148.
In vitro inhibition assays Mtb. Mtb H37Rv (ATCC 27294) was grown in
Middlebrook 7H9 broth medium supplemented with OADC (Difco Laboratories,
Detroit, MI, USA), 0.05% glycerol and 0.05% Tween-80. Freshly seeded cultures
were grown at 37 C, for B14 days, to mid-exponential phase (OD600 0.4–0.8) for
use in the inhibition assays. The effect of dihydrosansanmycin analogues against
the growth of Mtb H37Rv was measured by a resazurin reduction microplate assay,
using the procedure previously described by Taneja and Tyagi34. Mtb grown to
mid-exponential phase (OD600 0.4–0.8) was diluted to OD600 0.002 in 7H9S
medium (Middlebrook 7H9 with 10% albumin, dextrose, catalase (ADC, Moregate
Biotech), 0.05% glycerol, 0.05% Tween-80, 1% tryptone; 96-well microtiter plates
were set up with 100 ml inhibitors, serially diluted into 7H9S. Diluted Mtb (100 ml,
representing B2 104 CFUml 1) was added to each well. Plates were incubated
for 5 days at 37 C in a humidiﬁed incubator before the addition of a 0.02%
resazurin solution (30ml) and 20% Tween-80 (12.5 ml) to each well. Sample
ﬂuorescence was measured after 24 h on a BMG Labtech Polarstar Omega
instrument with an excitation wavelength of 530 nm and emission at 590 nm.
Changes in ﬂuorescence relative to positive control wells (Mtb H37Rv with no
inhibitor) minus negative control wells (no Mtb H37Rv) were plotted for
determination of MIC50 values. Rifampicin (R3501) and isoniazid (I3377) were
purchased from Sigma-Aldrich.
Mtb inhibition using infected macrophage culture. Mtb H37Ra strain (ATCC
25177) was grown in Middlebrook 7H9 broth medium supplemented with OADC
(Difco Laboratories), 0.05% glycerol and 0.05% Tween-80. Freshly seeded cultures
were grown at 37 C, for B14 days, to mid-exponential phase (OD600 0.4–0.8) for
use in the inhibition assays and used to infect a human macrophage-like cell line
(THP-1; ATCC TIB-202). THP-1 stocks were maintained at a culture density
between 1 105 and 1 106 cellsml 1 in RPMI-1640 medium (with phenol red,
25mM HEPES and 2mM L-glutamine) supplemented with 10% FBS (FBS-500)
and 0.05mM b-mercaptoethanol. THP-1 cells were plated in 96-well tissue culture
plates (Costar 3903; Corning) at a density of 1 105 cells/well with phorbol
myristic acetate (PMA; 100 nM) added. THP-1 cells were left to differentiate for
48 h at 37 C at 5% CO2. A cell suspension of sonicated Mtb H37Ra in RPMI-1640
cell culture medium was used to infect differentiated THP-1 cells at a multiplicity
of infection of 5 for 4 h at 37 C at 5% CO2. Supernatant was then removed from all
wells, THP-1 cells were washed with 200 ml phosphate buffered saline (PBS) three
times and were subsequently replenished with fresh RPMI-1640 cell culture
medium and incubated for a further 24 h at 37 C and 5% CO2. The sansanmycin
analogues were diluted in fresh RPMI-1640 cell culture medium and added to
corresponding wells. Positive controls were dissolved in 100% dimethyl sulfoxide
(DMSO) and diluted in 7H9 broth (Difco Becton Dickinson) with 10% ADC,
0.05% glycerol and 0.05% Tween 80 before adding to the wells. After 72 h of
incubation at 37 C at 5% CO2, tissue culture medium containing the test com-
pound was removed from the wells; the cells were washed with 200ml PBS, and
then lysed with sterile water containing 0.1% Triton X. Cell lysates were serially
diluted, 1:10, and plated on Middlebrook 7H11/OADC (283010; Difco) agar
through to 1:10,000 dilution. Agar plates were then incubated at 37 C for 3–4
weeks, after which the bacteria colonies were counted and CFU ml 1 of cell lysates
were determined.
Screen against a panel of bacterial strains. The effect of dihydrosansanmycin
analogues against 15 clinically relevant Gram-positive and Gram-negative bacteria
strains was evaluated using a procedure by Wong et al.35. Speciﬁcally, the screening
panel consisted of six Gram-positive strains (BSL1: Bacillus subtilis 168,
Staphylococcus epidermidis [ATCC 14990], Enterococcus faecium [ATCC 6569],
Listeria ivanovii [BAA-139]); BSL2: S. aureus [ATCC 29213], methicillin-resistant
S. aureus (MRSA) [BAA-44]) and nine Gram-negative strains (BSL1: Escherichia
coli K12 [BW 25113], Acinetobacter baumanii [NCIMB 12457], Enterobacter
aerogenes [ATCC 35029], Ochrobactrum anthropi [ATCC 49687], Providencia
alcalifaciens [ATCC 9886]; BSL2: Yersinia pseudotuberculosis [IP2666 pIBI],
Pseudomonas aeruginosa [ATCC 27835], Salmonella typhimurium LT2, Vibrio
cholerae O1 [biotype El Tor A1552]). All staphylococcal strains, L. ivanovii and
E. faecium were cultured in 10ml of tryptic soy broth (17 g tryptone, 3 g soytone,
2.5 g dextrose, 5 g NaCl and 2.5 g dipotassium phosphate in 1 l distilled water; pH
7.5). P. alcalifaciens, O. anthropi, E. aerogenes and A. baumanii were grown in
nutrient broth (Difco, USA), while B. subtilis, E. coli, V. cholerae, S. typhimurium,
P. aeruginosa and Y. pseudotuberculosis cultures were grown in Luria Broth
(10 g tryptone, 5 g yeast extract and 10 g NaCl in 1 l distilled water; pH 7.5).
All three media were autoclaved at 121 C for 30min. Inoculated cultures were
grown overnight in a shaker (200 r.p.m.; 30 C).
Overnight saturated cell cultures of pathogenic strains were diluted 1:1,000 with
fresh media and 30ml of culture dispensed into each well of sterile clear 384-well
plates. A total of 300 nl of DMSO prefraction stock solutions were pinned into
screening plates using a Perkin Elmer Janus MDT robot. After inoculation,
screening plates were stacked in a plate reader/shaker (Perkin Elmer EnVision) and
OD600 readings taken once per hour for 24 h. Computer generated growth curves
for serially diluted pure compounds (with the top ﬁnal screening concentration of
100 mM) were used to determine MIC values by correlating the OD600 reading at
the pre-exponential phase of the bacteria to the concentrations in individual wells.
MurX enzyme inhibition assays. Materials: UDP-N-acetyl-D-glucosamine
[glucosamine-14C(U)] ([14C]UDP-GlcNAc, Speciﬁc activity 300 mCi/mmol) was
obtained from American Radio Chemicals, UDP-MurNAc-pentapeptide was
obtained from BacWAN, University of Warwick, Coventry, UK (www.
warwick.ac.uk/bacwan). Dansyl-labelled UDP-MurNAc-pentapeptide was synthe-
sized from UDP-MurNAc-pentapeptide as described below. TLC Silica gel 60 F254
plates were procured from Merck (Germany). All other chemicals used were at
least analytical grade and were obtained from Sigma-Aldrich. Mtb mc2 6230 was a
generous gift from Dr William Jacobs, Albert Einstein College of Medicine,
New York.
Membrane preparation from Mtb mc2 6230. Mtb mc2 6230 was grown in 7H9
medium (supplemented with 0.5% (v/v) oleic acid, 0.5% (w/v) albumin, 0.2% (w/v)
dextrose, 24 mgml 1 D-pantothenate and 0.2% casamino acids). Washed cells were
resuspended in Buffer A (50mM MOPS pH 7.9, 5mM MgCl2, 5mM DTT, 10%
glycerol (v/v)), at 2ml g 1 of cells, and disrupted by probe sonication on ice with a
Sanyo Soniprep 150 (10 cycles of 60 s on and 90 s off). The whole cell lysates were
centrifuged at 5,000g for 20min at 4 C. The supernatant was further
centrifuged at 100,000g (for 1 h at 4 C) in an Optima TLX Ultracentrifuge
(Beckman). The membrane-enriched pellets were washed in Buffer A followed by
ultracentrifugation at 100,000g. The washed pellets were resuspended in Buffer A,
divided into aliquots and frozen at  80 C. The protein concentration of the
membrane-enriched fraction was estimated using a BCA protein assay kit (Pierce).
Preparation of dansylated UDP-MurNAc pentapeptide. Synthesis and
puriﬁcation UDP-MurNAc-pentapeptide was achieved by chemoenzymatic
recapitulation of the cytoplasmic synthetic pathway in vitro43. Desalted UDP-
MurNAc-pentapeptide in sterile water was mixed with an equal volume of acetone
and allowed to react overnight with a 42-fold molar ratio of dansyl chloride with
stirring. The reaction was quenched with a 10-fold molar excess of Tris-Cl pH 9 to
dansyl chloride before rotary evaporation to remove solvents. Dried products were
resuspended in 1ml sterile water and puriﬁed by size exclusion chromatography on
a Superdex peptide 10/300 column (GE Healthcare) pre-equilibrated with 1.5 CV
0.1M ammonium bicarbonate. Dansylated UDP-MurNAc-pentapeptide is the ﬁrst
peak to elute in this procedure with a characteristic absorbance at 340 and 280 nm.
Fractions containing the required product were freeze dried 4 times and
resuspended in a small volume of sterile water. Quantiﬁcation and purity were
conﬁrmed by absorbance and mass spectrometry, respectively.
Radiochemical Mtb MurX inhibition assay. Assay mixtures (200 ml) contained
50mM MOPS pH 7.9, 5mM MgCl2, 5mM DTT, 10% glycerol (v/v), 0.1% CHAPS,
100 mM ATP, 25 mM UDP-MurNAc-pentapeptide, 0.5 mM [14C] UDP-GlcNAc,
and varying concentrations of inhibitor (initial screening was carried out at a single
concentration of 200 nM and the most potent compounds were screened at a range
of concentrations to determine IC50 values, Supplementary Figs 34–37). Reactions
were initiated by the addition of 400–500 mg of Mtb mc2 6230 membrane protein
and incubated at 37 C for 1 h. Reactions were stopped by the addition of 6ml of
chloroform/MeOH (2:1), followed by low speed centrifugation and the organic
extract was moved to a second tube. Extracts were back washed twice [once with
water (800 ml) and then with chloroform/MeOH/water (3:47:48)], evaporated to
dryness under a nitrogen stream, and dissolved in chloroform/MeOH (2:1 v/v). An
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aliquot was subjected to liquid scintillation counting (LS 6500, Beckman Coulter); a
second aliquot was subjected to TLC (Silica gel 60 F254) developed in chloroform/
MeOH/water/ammonium hydroxide (88:48:10:1). Distribution of radioactivity was
detected by phosphorimaging (Typhoon TRIO, Amersham Biosciences) and
quantiﬁed with ImageQuant TL v2005 software (Amersham Biosciences). IC50
values were calculated by using GraFit Software (Version 5.0.13).
Fluorescence-basedMtb MurX inhibition assay. Continuous ﬂuorescence MurX
assays (100 ml in volume) were carried out in vitro at 25 C in an assay buffer
consisting of 83mM Tris pH 7.5, 21mM MgCl2, 6% glycerol, 0.1% TritonX-100,
15mM dansylated UDP-MurNAc-pentapeptide, 40 mgml 1 polyisoprenyl
phosphate and varying concentrations of inhibitor42. Reactions were initiated by
the addition of 60–70 mg of Mtb mc2 6230 membrane protein and ﬂuorescence was
monitored at 340 and 530 nm for excitation and emission, respectively. Assays were
carried out in duplicate and IC50 values were calculated using GraFit Software
(Version 5.0.13, Supplementary Figs 42–44). A further inhibition assay was carried
out for analogue 37 at an increased concentration of polyisoprenylphosphate
(160 mgml 1, Supplementary Fig. 45). Assays were also performed at a ﬁxed
concentration of UDP-MurNAc-pentapeptide (15 mM) and a range of exogenous
polyisoprenylphosphate concentrations. This enabled the determination of the
apparent Km and Vmax values with respect to the polyisoprenylphosphate substrate.
The endogenous polyisoprenylphosphate concentration in the extracted membrane
was calculated to be 0.28 mgmg 1 of membrane protein.
Stability studies in human and mouse plasma. Human blood from
nonidentiﬁable volunteer donors was sourced from the Australian Red Cross Blood
Service under a supply agreement approved by the Monash Human Research
Ethics Committee. Mouse blood was collected in-house under tissue harvesting
protocols approved by the Monash Institute of Pharmaceutical Sciences Animal
Ethics Committee. Pooled human and Swiss outbred mouse plasma samples were
thawed and spiked with test compound solutions prepared in DMSO/acetonitrile/
water (20:40:40) to provide a ﬁnal compound concentration of 1,000 ngml 1 and
ﬁnal DMSO and acetonitrile concentrations of 0.2% and 0.4% (v/v), respectively.
Plasma was vortex mixed and aliquots (50ml) were transferred to fresh micro-
centrifuge tubes and incubated at 37 C. At various time points over the 6 h
incubation period, duplicate plasma samples were removed and immediately
snap-frozen in dry ice. All samples were stored frozen at  80 C until analysis by
LC–MS. Samples were processed by protein precipitation using a two-fold excess of
acetonitrile followed by centrifugation. Analysis of the supernate was conducted
using a Waters (Milford, MA) Acquity UPLC coupled to a Waters Micromass
Quattro Premier mass spectrometer operated in positive electrospray ionization
mode with multiple reaction monitoring. The cone voltage was 45V, collision
energy was 30, 30 and 40V for 25, 36 and 37, respectively, and m/z transitions
were 782.304126.06 (25), 826.324170.16 (36) and 888.394126.06 (37).
Processed samples (3 ml) were injected onto a Supelco Ascentis Express RP Amide
column (50 2.1mm, 2.7 mm) and analytes eluted using a water/acetonitrile
(each containing 0.05% formic acid) gradient over 4min with a ﬂow rate was
0.4mlmin 1. Sample concentrations were quantitated by comparison to a
calibration curve prepared in blank human or mouse plasma.
Stability studies in human and mouse liver microsomes. The metabolic stability
was assessed by incubating each test compound (0.5 mM) in duplicate with
human and mouse liver microsomes (XenoTech, Kansas City, KS) at 37 C and
0.4mgml 1 microsomal protein. The metabolic reaction was initiated by the
addition of an NADPH-regenerating system and quenched at various time points
over a 60min incubation period by the addition of acetonitrile containing diaze-
pam as internal standard. Control samples (containing no NADPH) were included
and quenched at 2, 30 and 60min to monitor for potential degradation in the
absence of cofactor. Samples were centrifuged and the supernatant analysed by
LCMS. Analysis was conducted using a Waters Acquity UPLC coupled to a Waters
Xevo G2 QTOF mass spectrometer operated in positive electrospray ionization
MSE mode with a cone voltage of 30V. Samples (5 ml) were injected onto an
Ascentis Express Amide column (50 2.1mm, 2.7 mm) and eluted using a water/
acetonitrile (both containing 0.05% formic acid) gradient over 4min at a ﬂow rate
of 0.4mlmin 1. Degradation rate half-lives and in vitro intrinsic clearance values
were determined from the ﬁrst order degradation proﬁles.
Data availability. Data supporting the ﬁndings of this study are available within
the article and its Supplementary Information ﬁles and from the corresponding
author upon reasonable request.
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